GLP-1 receptor agonists have been proven to be associated with significant beneficial cardiovascular effects, improvement in non-alcoholic fatty liver disease, and diabetic nephropathy [68,73,74]. The gene discussed is GLP1R; the disease is diabetic kidney disease.